- Details
- Mark Rubin joins Alicia Morgans to discuss emerging therapies and emerging therapeutic targets in prostate cancer. Topics covered include types of resistance, epigenetic therapies, and EZH2 inhibitors. Dr. Rubin also shares his thoughts on how he sees molecular pathology impacting cancer care in the next decade. Biographies: Mark A. Rubin, MD, Professor, Principal Investigator, and Director of Dep...
|
- Details
- Silke Gillessen facilitates the metastatic castration-resistant prostate cancer session discussion during the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 about treatment recommendations for metastatic castration-resistant prostate cancer. Topics covered include chemotherapy decisions regarding docetaxel and cabazitaxel, ADT, AR pathways, clinical trials versus real-world treatment,...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Bertrand Tombal presents de-escalation strategies in the management of metastatic hormone-sensitive prostate cancer (mHSPC) Biographies: Bertrand Tombal, MD, PhD, Chairman of the Department of Surgery and Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels,...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Christopher Sweeney presents treatment intensification strategies in metastatic hormone-sensitive prostate cancer (mHSPC), focusing on triplet therapies. Biographies: Christopher Sweeney, MBBS, Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Related Content: APCCC 2022: Treatme...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Karim Fizazi presents when low-volume disease on conventional imaging becomes high-volume on next-generation imaging in mHSPC, we should treat these patients like low volume patients. Biographies: Karim Fizazi, MD, Ph.D., is a medical oncologist at Gustave Roussy, and a full professor in Oncology at the University of...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Michael Hofman presents how frequently low-volume disease on conventional imaging becomes high-volume on next-generation imaging in the management of metastatic hormone-sensitive prostate cancer (mHSPC). Biographies: Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS, Molecular Imaging & Therapeutic Nuclear Medicine,...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Andrew Armstrong presents the uptake of new treatment options for mHSPC in real life, including education, access, use, and diversity. Biographies: Andrew Armstrong, MD, Professor of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC Related Content: APCCC 2022: The...
|
- Details
- Dan George discusses the Ironman study, a significant international registry aimed at enhancing outcomes for men with advanced prostate cancer. This cohort study, distinct from clinical trials, longitudinally tracks patients to identify unmet needs and intervention opportunities in practice settings, rather than trial environments. It focuses on two patient groups: those with de novo metastatic, c...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference, Johann de Bono presents the role of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) patients focusing on the case for a selected, judicious use of PARP inhibitors in this setting. Biographies: Johann de Bono, MD, PhD, Professor of Cancer Research and a Professor in Experimental Cancer Medicine at The Institute o...
|
- Details
- At the APCCC 2022, Charles J Ryan presents the Importance of Lifestyle and Prevention of Complications in Advanced Prostate Cancer: How to Take Care of Brain and Mood? Biographies: Charles J. Ryan, MD, the President and Chief Executive Officer of The Prostate Cancer Foundation (PCF), the world’s leading philanthropic organization dedicated to funding life-saving prostate cancer research. Charles J...
|
